Report Overview

Canadas Psoriasis market size stood at around USD XX.X billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of around XX.X% during the forecast period.

Psoriasis affected nearly 1 million Canadians. The most common form is plaque psoriasis, which affected approximately 90% of patients. Up to 30% of patients with psoriasis have or will have arthritis. Having psoriasis may increase the risk of developing other chronic systemic diseases, including heart attack and stroke, diabetes, cancer, and liver disease. According to a national patient survey, psoriasis and related conditions impose a severe burden on the daily lives of Canadians with a history of moderate to severe psoriasis. Over one-third of respondents (176 of 500) viewed their skin condition as a significant problem in their daily life. The perception seemed to correlate with the extent of the disease.



Market Drivers

Psoriasis affects an estimated 1-3% of people in Canada. The growth of the Psoriasis market is majorly driven by factors such as increasing public awareness, approval of new drugs, and boost in psoriasis Research and Development investment. The rise in psoriasis patients in the past few years can also be attributed to climate change, stress, and unhealthy lifestyle. Furthermore, Psoriasis networks have been founded to substantially improve the quality of care for patients suffering from psoriasis in Canada. The strategy is to join forces of those dermatologists and departments with high expertise in the treatment of psoriasis and psoriatic arthritis, and that regard themselves as top-level providers for this disease.